Lil
03-22-2006, 08:32 AM
IRVINE, Calif., March 22 /PRNewswire-FirstCall/ -- Dermisonics, Inc.
(OTC Bulletin Board: DMSI.OB), a pioneer in the development of painless
injection-free ultrasonic transdermal drug-delivery technologies with broad
pharmaceutical and consumer applications, announced today that the Company has
agreed to sell a total of 7.2 million common shares of the Company's capital
stock to two Luxembourg-based SICAV funds for net proceeds of $4,134,240. The
placement will be completed in reliance upon the exemption from the
registration requirements of the Securities Act afforded by Regulation S as
promulgated under the Securities Act of 1933. Dermisonics will use the net
proceeds derived from the financing to continue the development and testing of
the U-Strip, U-Wand and A-Wand systems, to explore new applications for the
Company's intellectual property estate and to negotiate strategic marketing
alliances with companies in the cosmetic, pharmaceutical, and antiseptic
industries. It is anticipated that the closing of this transaction will occur
in the next 30 days.
Bruce Haglund, CEO of Dermisonics, commented, "This financing will give us
the resources to complete our human pilot trials for our insulin studies and
accelerate our R&D and marketing programs simultaneously on three critical
fronts:
-- The $17.6 billion skin care market and the anti-aging needs of the 270
million graying baby boomers in the U.S. and Europe alone,
-- The $19 billion drug delivery market treating the 55 million diabetics
worldwide forced to use painful needles to survive this debilitating
disease, and
-- The $1.2 billion antiseptic market for consumers at home and to combat
the critical problem of infections for soldiers wounded on the
battlefield."
About Dermisonics, Inc. -- Dermisonics is an intellectual property company
and advanced technology incubator that is primarily focused on developing and
marketing its transdermal and subdermal technologies for applications in the
drug (U-Strip), skin care (U-Wand), and antiseptic (A-Wand) fields. Its
breakthrough system, called the U-Strip, facilitates the efficient and needle-
free delivery of drugs with large molecular structures into the bloodstream.
This system is based on a radical integration of microelectronics and
ultrasonic science with a product-carrying patch and represents a quantum leap
in non-invasive, transdermal delivery technology. Tests have shown that the U-
Strip facilitates the transdermal delivery of Insulin as well as potentially
at least 175 other existing drugs through the pores of the skin.
Conventionally available transdermal technology cannot effectively deliver
these drugs due to their large molecular size. The Company has also developed
major line extensions for applications in the medical (Antiseptic Wand) and
skin care (U-Wand) fields.
For further information contact Bruce Haglund, CEO.
bruce.haglund@dermisonics.com
Dermisonics, Inc.
2 Park Plaza, Suite 450,
Irvine, California 92614
U.S.A.
888-401-DERM (3376) Toll Free
949-733-1101 Phone
949-733-1188 Fax
North American Investor Relations Contact:
Brent Pierce, International Marketing Trend, Inc.
Phone: 877-676-4447
European Investor Relations Contact:
Michael Drepper
Phone: +49-621-430-6130
investor-germany@dermisonics.com
For additional information, please visit www.dermisonics.com.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that are based upon current expectations or beliefs, as
well as a number of assumptions about future events. Although the Company
believes that the expectations reflected in the forward-looking statements and
the assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have been
correct. The reader is cautioned not to put undue reliance on these forward-
looking statements, as these statements are subject to numerous factors and
uncertainties, including but not limited to adverse economic conditions,
intense competition, lack of meaningful research results, entry of new
competitors and products, adverse federal, state and local government
regulation, inadequate capital, unexpected costs and operating deficits,
increases in general and administrative costs, termination of contracts or
agreements, technological obsolescence of the Company's products, technical
problems with the Company's research and products, price increases for
supplies and components, litigation and administrative proceedings involving
the Company, the possible acquisition of new businesses or that result in
operating losses or that do not perform as anticipated, unanticipated losses,
the possible fluctuation and volatility of the Company's operating results,
financial condition and stock price, losses incurred in litigating and
settling cases, dilution in the Company's ownership of its business, adverse
publicity and news coverage, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and research
scientists, changes in interest rates, inflationary factors, and other
specific risks. In addition, other factors that could cause actual results to
differ materially are discussed in the Company's most recent Form 10-QSB and
Form 10-KSB filings with the Securities and Exchange Commission.
SOURCE Dermisonics, Inc.
Contact Information:
Bruce Haglund, CEO, Toll Free, 1-888-401-DERM (3376), or +1-949-733-1101, or fax, +1-949-733-1188, or bruce.haglund@dermisonics.com, or Michael Drepper, European Investor Relations, +49-621-430-6130, or investor-germany@dermisonics.com, both of Dermisonics, Inc.; or Brent Pierce, International Marketing Trend, Inc., 1-877-676-4447
WebSite:
http://www.dermisonics.com
(OTC Bulletin Board: DMSI.OB), a pioneer in the development of painless
injection-free ultrasonic transdermal drug-delivery technologies with broad
pharmaceutical and consumer applications, announced today that the Company has
agreed to sell a total of 7.2 million common shares of the Company's capital
stock to two Luxembourg-based SICAV funds for net proceeds of $4,134,240. The
placement will be completed in reliance upon the exemption from the
registration requirements of the Securities Act afforded by Regulation S as
promulgated under the Securities Act of 1933. Dermisonics will use the net
proceeds derived from the financing to continue the development and testing of
the U-Strip, U-Wand and A-Wand systems, to explore new applications for the
Company's intellectual property estate and to negotiate strategic marketing
alliances with companies in the cosmetic, pharmaceutical, and antiseptic
industries. It is anticipated that the closing of this transaction will occur
in the next 30 days.
Bruce Haglund, CEO of Dermisonics, commented, "This financing will give us
the resources to complete our human pilot trials for our insulin studies and
accelerate our R&D and marketing programs simultaneously on three critical
fronts:
-- The $17.6 billion skin care market and the anti-aging needs of the 270
million graying baby boomers in the U.S. and Europe alone,
-- The $19 billion drug delivery market treating the 55 million diabetics
worldwide forced to use painful needles to survive this debilitating
disease, and
-- The $1.2 billion antiseptic market for consumers at home and to combat
the critical problem of infections for soldiers wounded on the
battlefield."
About Dermisonics, Inc. -- Dermisonics is an intellectual property company
and advanced technology incubator that is primarily focused on developing and
marketing its transdermal and subdermal technologies for applications in the
drug (U-Strip), skin care (U-Wand), and antiseptic (A-Wand) fields. Its
breakthrough system, called the U-Strip, facilitates the efficient and needle-
free delivery of drugs with large molecular structures into the bloodstream.
This system is based on a radical integration of microelectronics and
ultrasonic science with a product-carrying patch and represents a quantum leap
in non-invasive, transdermal delivery technology. Tests have shown that the U-
Strip facilitates the transdermal delivery of Insulin as well as potentially
at least 175 other existing drugs through the pores of the skin.
Conventionally available transdermal technology cannot effectively deliver
these drugs due to their large molecular size. The Company has also developed
major line extensions for applications in the medical (Antiseptic Wand) and
skin care (U-Wand) fields.
For further information contact Bruce Haglund, CEO.
bruce.haglund@dermisonics.com
Dermisonics, Inc.
2 Park Plaza, Suite 450,
Irvine, California 92614
U.S.A.
888-401-DERM (3376) Toll Free
949-733-1101 Phone
949-733-1188 Fax
North American Investor Relations Contact:
Brent Pierce, International Marketing Trend, Inc.
Phone: 877-676-4447
European Investor Relations Contact:
Michael Drepper
Phone: +49-621-430-6130
investor-germany@dermisonics.com
For additional information, please visit www.dermisonics.com.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that are based upon current expectations or beliefs, as
well as a number of assumptions about future events. Although the Company
believes that the expectations reflected in the forward-looking statements and
the assumptions upon which they are based are reasonable, it can give no
assurance that such expectations and assumptions will prove to have been
correct. The reader is cautioned not to put undue reliance on these forward-
looking statements, as these statements are subject to numerous factors and
uncertainties, including but not limited to adverse economic conditions,
intense competition, lack of meaningful research results, entry of new
competitors and products, adverse federal, state and local government
regulation, inadequate capital, unexpected costs and operating deficits,
increases in general and administrative costs, termination of contracts or
agreements, technological obsolescence of the Company's products, technical
problems with the Company's research and products, price increases for
supplies and components, litigation and administrative proceedings involving
the Company, the possible acquisition of new businesses or that result in
operating losses or that do not perform as anticipated, unanticipated losses,
the possible fluctuation and volatility of the Company's operating results,
financial condition and stock price, losses incurred in litigating and
settling cases, dilution in the Company's ownership of its business, adverse
publicity and news coverage, inability to carry out research, development and
commercialization plans, loss or retirement of key executives and research
scientists, changes in interest rates, inflationary factors, and other
specific risks. In addition, other factors that could cause actual results to
differ materially are discussed in the Company's most recent Form 10-QSB and
Form 10-KSB filings with the Securities and Exchange Commission.
SOURCE Dermisonics, Inc.
Contact Information:
Bruce Haglund, CEO, Toll Free, 1-888-401-DERM (3376), or +1-949-733-1101, or fax, +1-949-733-1188, or bruce.haglund@dermisonics.com, or Michael Drepper, European Investor Relations, +49-621-430-6130, or investor-germany@dermisonics.com, both of Dermisonics, Inc.; or Brent Pierce, International Marketing Trend, Inc., 1-877-676-4447
WebSite:
http://www.dermisonics.com